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Abstract

Background: The surgical techniques and devices used to perform radical cystectomy have evolved significantly with the advent of laparoscopic and robotic methods. The da Vinci Single-Port (SP) platform (Intuitive
Surgical, Inc., Sunnyvale, CA) is an innovation that allows a surgeon to perform robot-assisted radical cystectomy (RARC) through a single incision. To determine if this new tool is comparable to its multiport (MP)
predecessors, we reviewed a single-surgeon experience of SP RARC.
Materials and Methods: We identified patients at our institution who underwent RARC between August 2017
and June 2020 by one surgeon at our institution (n = 64). Using propensity scoring analysis, patients whose
procedure were performed with the SP platform (n = 12) were matched 1:2 to patients whose procedure was
performed with the MP platform (n = 24). Univariable analysis was performed to identify differences in any
perioperative outcome, including operative time, estimated blood loss (EBL), lymph node yield, 90-day
complication/readmission rates, and positive surgical margin (PSM) rates.
Results: Patients who had an SP RARC on average had a lower lymph node yield than those who had an
MP RARC (11.9 vs 17.1, p = 0.0347). All other perioperative outcomes, including operative time, EBL, 90-day
complication rates, 90-day readmission rates, and PSM rates, were not significantly different between the SP
and MP RARC groups.
Conclusions: Based on their perioperative outcomes, the SP platform is a feasible alternative to the MP platform when performing RARC. The SP’s perioperative outcomes should continue to be evaluated as more SP
RARCs are performed.
Keywords: cystectomy, robotic surgical procedures, positive surgical margins, operative time
Introduction

R

obot-assisted radical cystectomy (RARC) has been
shown to provide perioperative benefits typically associated with minimally invasive surgery. These benefits include reduced incisional pain, blood loss, and length of stay
when compared to open approaches.1 Furthermore, RARC is
associated with noninferior oncologic outcomes with regard
to progression-free survival rates at 3 years.2 These studies
have been based on multiport (MP) platforms where each
robotic arm and camera requires its own surgical incision
and port.
The da Vinci Single-Port (SP) platform (Intuitive Surgical, Inc., Sunnyvale, CA) allows RARC to be even less

invasive than the conventional MP approach. The SP platform provides the surgeon access to three multijointed robotic arms and a multijointed camera, all of which fit through
a single 25 mm channel. The feasibility of performing both
RARC and urinary diversions with this system has been previously described.3,4
Although it shares goals and design choices with its predecessors, the SP platform is not a direct translation of the MP
platforms. The addition of joints to the bodies of laparoscopic
instruments allows surgeons to operate through a single port,
although minimizing instrument clashing. However, the lack
of a second joint directly at the wrists of these instruments
requires additional working space for some motions.5 We
hypothesize that the use of an SP platform during RARC may
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impact perioperative outcomes when compared to conventional MP RARC because of differences in each platform’s
design and functionality.
A comparative cohort between MP RARC and SP RARC
is necessary to evaluate the perioperative outcomes of this
new surgical tool. To evaluate these outcomes, we reviewed
12 consecutive SP RARCs within a single-surgeon series
and compared their perioperative outcomes to a propensitymatched cohort of patients who underwent MP RARC.
Materials and Methods
Subjects

After Institutional Review Board approval was granted,
we reviewed the medical records of patients who underwent
RARC with an ileal conduit or neobladder diversion from
August 2017 to June 2020 performed by a single surgeon,
who has 3 years of post-training experience with the da Vinci
MP platform and a caseload of over 90 RARCs. We identified
12 patients who underwent SP RARC and 52 patients who
underwent MP RARC.
Propensity matching

To reduce the impact of known clinical predictors of perioperative outcomes, we used nearest neighbor (1:2) propensity score matching to pair those who underwent SP RARC
with patients who underwent MP RARC. Matching was
based on the patient’s age, sex, body mass index (BMI),
T stage after transurethral resection of bladder tumor
(TURBT), prior history of pelvic surgery, prior history of
radiation, use of neoadjuvant chemotherapy, and type of
urinary diversion.6–9 The final cohorts included 12 patients
who underwent SP RARC and 24 patients who underwent
MP RARC.

FIG. 1. Extirpative RARC
steps. (A) Initial view of the
intraperitoneal space before
instrument docking.
(B) Dissection and division
of the ureter; Arrow: ureter.
(C) Dissection and clipping
of the bladder pedicles;
Arrow: clipped vessel.
(D) Division of the DVC
with electrocautery; Arrow:
DVC. DVC = dorsal venous
complex; RARC = robotassisted radical cystectomy.
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SP RARC surgical technique
Port placement and docking. The initial straight in placement of a midline SP trocar is accomplished with an open
Hasson technique.10 A 12 mm AirSeal assistant port is
placed in the left lower quadrant. The da Vinci SP robot is
docked (Fig. 1A) and loaded with fenestrated bipolar forceps in channel 1, Cadiere forceps in channel 2, and monopolar curved scissors in channel 3. These instruments are
used until the creation of the ureteral-bowel anastomoses.
Extirpative portion of RARC. The extirpative portion
of SP RARC is performed as previously described for MP
RARC.11 Briefly, the left ureter is identified at the confluence
of the bifurcation of the common iliac and the vas deferens.
The ureter is dissected free caudad to the level of the bladder.
Weck Hem-o-lok clips are applied to the distal ureter,
which is then divided (Fig. 1B). This is repeated for the right
ureter.
For female patients, the gonadal vessels are controlled
with Weck Hem-o-lok clips and the broad and round ligament are controlled with bipolar electrocautery and subsequently divided. Utilizing a ringed forceps with a sponge in
the vagina, an incision is made over the posterior peritoneum
at the level of the cervix. Once the sponge is visualized after
entry into the vaginal canal, the bladder pedicles are taken
with a combination of Weck Hem-o-lok clips and bipolar
electrocautery. The endocervical fascia is dissected laterally
and the space of Retzius is developed. The anterior vagina
and urethra are dissected free using electrocautery dissection.
For male patients, the posterior reflection of the peritoneum is divided to expose the seminal vesicles and the distal
vas deferens. Denonvilliers’ fascia is identified and bluntly
dissected posteriorly. The medial umbilical ligaments are
ligated with Weck Hem-o-lok clips and divided. The pedicles
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of the bladder are controlled with sequential Weck Hem-olok clips and electrocautery dissection (Fig. 1C). Once the
endopelvic fascia is encountered, the space of Retzius is
developed. A nerve-sparing procedure with minimal opening
of the endopelvic fascia is performed for low-risk patients
who desire retained erectile function. The dorsal venous
complex is then controlled with electrocautery dissection
(Fig. 1D). The posterior plane of the dissection is bluntly
retracted from Denonvilliers fascia until the urethra is isolated. The urethra is divided sharply. The Foley catheter is
brought to the midline, ligated with Weck Hem-o-lok clips
and divided, and the rectourethralis muscle is divided.
Retraction during the preceding steps is challenging owing
to the seemingly reduced grip strength and unique arm constraints on the SP platform.
The bilateral pelvic lymph
node dissection is performed using the genitofemoral nerve,
Cooper’s ligament, the obturator nerve, and the common iliac
artery as boundaries of dissection.
Pelvic lymph node dissection.

Intracorporeal ileal conduit creation. Ten patients received an ileal conduit through the following steps: a 20 cm
segment of distal ileum is isolated 20 cm from the ileocolic
junction with two 60 mm tan loads of an Endo-GIA stapler
(Medtronic, Minneapolis, MN) through the assistant port
(Fig. 2A). The bowel-to-bowel anastomosis is performed in a
side-to-side functional end-to-end manner with two 60 mm
tan loads performing the side-to-side anastomosis and another 60 mm tan load performing the closure of the segment
(Fig. 2B–D).
The left ureter is tunneled under the sigmoid mesentery
and both ureters are widely spatulated (Fig. 3A). An enterotomy is created in the ileal conduit with the monopolar
curved scissors. The monopolar curved scissors are removed
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from channel 3 and replaced with a needle driver. A Bricker
ileal ureteral anastomosis is performed with 4-0 Monocryl
suture in a running manner (Fig. 3B). A single J stent is
placed in the ureter as much as the level of the kidney before
completion of the anastomosis (Fig. 3C, D). The needle driver is removed from channel 3 and replaced with the monopolar curved scissors to repeat the creation of an ileal ureteral
anastomosis for the remaining ureter. The pelvis is then irrigated with antibiotic solution and the distal end of the conduit is marked with a 2-0 Vicryl suture.
The distal end of the conduit is brought as much as the right
upper quadrant (Fig. 4A). The trocars are removed. After
excision of the skin, the ostomy is matured using 2-0 and 3-0
chromic suture in a Bricker manner (Fig. 4B–D).12
Intracorporeal neobladder creation. Two patients received orthotopic neobladders. Neobladder creation was performed as previously described for MP RARC.11 Briefly, a
60 cm segment of distal ileum is isolated 20 cm from the
ileocolic junction with two 60 mm tan loads. The bowel-tobowel anastomosis is performed in a side-to-side functional
end-to-end manner with three 60 mm tan loads. The bowel
segment is sewn to the urethral stump with 3-0 V-Loc suture
in running manner. The bowel segment is then opened along
the antimesenteric border. The back wall of the bowel segment is sewn together with a 2-0 V-Loc suture in running
manner. The ureteral-to-neobladder anastomoses are created with a 4-0 Monocryl suture placed in running manner.
Single J ureteral stents are placed in both ureters. The ureters
are brought to the lower left quadrant. A 4-0 chromic suture
is used to purse string the neobladder around the stents. The
anterior neobladder is closed with 2-0 V-Loc suture in a running manner. The final Foley catheter is placed through the
urethra, and the balloon is inflated to 7 mL. The neobladder is
irrigated with 120 mL of normal saline to detect leaks.

FIG. 2. Creation of the
ileal conduit and bowel-tobowel anastomosis. Obtaining the angles necessary to
perform this portion of the
procedure can be difficult.
The images in this study
demonstrate the best approach for accomplishing the
anastomosis. (A) Isolation of
a segment of ileum using an
End-GIA stapler; Arrow:
ileum. (B) Anastomosis of
the bowel segments in a sideto-side manner; Arrow: ileum
still in communication with
the GI tract. (C) End-to-end
closure of the bowel-tobowel anastomosis; Arrow:
open end of bowel-to-bowel
anastomosis before stapling.
(D) Completed bowel-tobowel anastomosis; Arrow:
end-to-end staple line of
bowel-to-bowel anastomosis.
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FIG. 3. Creation of the
ileal ureteral anastomosis.
(A) Spatulation of the distal
ureter; Arrow: spatulated
ureter. (B) Initial knot of the
ileoureteral anastomosis;
Arrow: spatulated ureter
above arrow tip and ileal
enterotomy below.
(C) Single J stent placed in
the ureter before completion
of anastomosis; Arrow:
single J stent within the
ureter. (D) Completed ileal
ureteral anastomosis; Arrow:
ileoureteral anastomosis.

Closure and postoperative management of stents and
drains. The fascia of the assistant and camera port is closed

with 0 Vicryl suture. The skin of the port sites is closed with
4-0 Monocryl suture and reapproximated with Steri-Strip
dressings.
Each patient is managed on an Enhanced Recovery After
Surgery (ERAS) pathway, which includes an epidural for
pain control, minimizes narcotic use, and emphasizes early
activity postoperatively. Any drain is monitored and removed on postoperative day 3. Ureteral stents are removed on

FIG. 4. (A) Bowel after
intracorporeal creation of the
ileal conduit; Arrow: distal
end of the conduit held in
place before moving it to the
surface for ostomy formation. (B–D) Patient abdomen
after completion of an ileal
conduit and skin closure.
Arrow: Bricker urostomy.
Triangle: midline SP trocar
site after closure with 4-0
Monocryl with and without
Steri-Strip dressing. Star:
assistant port site with and
without drain in place.
SP = single port.

postoperative day 7 to 10. Patients with neobladders have a
cystogram on postoperative day 21 and their Foley catheter is
removed if no leak is present.
Perioperative outcome measures

Assessed perioperative outcomes included the following:
hospital length of stay, 90-day readmission rate, 90-day complication rate, estimated blood loss (EBL), operative time, lymph
node yield, and rate of positive surgical margins (PSMs).

PERIOPERATIVE OUTCOMES OF SINGLE-PORT ROBOTIC CYSTECTOMY
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Table 1. Clinical Characteristics and Patient Demographics
Unmatched
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Clinical characteristic
Mean age, years (SD)
Sex, n (%)
Female
Male
Mean BMI, kg/m2 (SD)
Type of urinary diversion, n (%)
Ileal conduit
Neobladder
T stage after TURBT, n (%)
T1
T2
History of pelvic surgery, n (%)
History of neoadjuvant chemotherapy, n (%)
History of pelvic radiation, n (%)

MP

SP

(n = 52)

(n = 12)

69.0 (6.6)

64.1 (11.7)

13 (25.0)
39 (75.0)
26.6 (7.1)

3 (25.0)
9 (75.0)
27.2 (4.7)

43 (82.7)
9 (17.3)

10 (83.3)
2 (16.7)

11
41
17
30
9

2
10
3
7
0

Matched
MP

SP

p-Value

(n = 24)

(n = 12)

p-Value

0.059
1

67.3 (6.6)

64.1 (11.7)

0.308
1

7 (29.2)
17 (70.8)
27.1 (7.8)

3 (25.0)
9 (75.0)
27.2 (4.7)

20 (83.3)
4 (16.7)

10 (83.3)
2 (16.7)

3
21
7
11
0

2
10
3
7
0

0.79
1
1

(21.2)
(78.8)
(32.7)
(57.7)
(17.3)

(16.7)
(83.3)
(25.0)
(58.3)
(0)

0.863
1
0.274

0.977
1
1

(12.5)
(87.5)
(29.2)
(45.8)
(0)

(16.7)
(83.3)
(25.0)
(58.3)
(0)

1
0.724

BMI = body mass index; MP = multiport; SD = standard deviation; SP = single port; TURBT = transurethral resection of bladder tumor.

Readmissions were defined as having any readmission
within 90 days to the operating facility or any associated
hospital. Complications were defined as having any ClavienDindo Grade II complication or greater within 90 days of
surgery.13
Statistical analysis

Comparisons were made using the chi-square test of independence and Wilcoxon rank-sum test for categorical and
continuous variables, respectively, to assess for differences
between those who underwent MP vs SP RARC. Statistical
significance was defined by a p-value of <0.05. All propensity
matching and statistical analysis were done in R, Version
3.6.2.
Results

The baseline clinical characteristics for the patients in this
study are summarized in Table 1. No baseline characteristic was significantly different between the two groups after
propensity matching, including age, BMI, sex, type of urinary
diversion, or T stage after TURBT. There were also no
differences in their past medical history for rates of pelvic
radiation, pelvic surgery, or neoadjuvant chemotherapy.
Perioperative outcomes are summarized and compared
in Table 2. Patients who underwent SP RARC on average
had a lower lymph node yield during surgery than MP
RARC patients with an average of 11.9 and 17.1 ( p = 0.034)
lymph nodes, respectively. Length of stay (5.4 vs 5.9 days,
p = 0.945), EBL (117 vs 148 mL, p = 0.080), operative time
(387 vs 418 minutes, p = 0.247), and rate of PSMs (8.3 vs
4.2%, p = 0.607) were not statistically different between patients who had SP or MP RARC, respectively.
Discussion

Our single-surgeon propensity-matched cohorts suggest
that patients undergoing RARC experience similar perioperative outcomes when the SP or MP robotic platform is used

to perform the procedure. Uniquely, lymph node yield is
found to be lower for cases with the SP platform. These
findings indicate that the SP platform is a comparable and
feasible alternative to the MP platform when performing an
RARC.
Given that a surgeon is experienced with MP RARC,
perioperative outcomes, including PSM, 90-day complication/
readmission rate, EBL, operative time, and length of stay
during a surgeon’s initial experience with the SP platform,
have similar outcomes to those patients who undergo MP
RARC. Previous studies have shown the learning curve of
the MP platform significantly impacts PSM and operative
time.14,15 Although MP cases had a higher average operative
time that was not statistically significant, this is likely attributable to the reduced role of surgical trainees during SP
cases. Considering this, neither our data nor an investigation
into the initial experience of SP robot-assisted laparoscopic

Table 2. Comparison of Perioperative Outcomes
Between Patients Receiving Single-Port Vs
Multiport Robot-Assisted Radical Cystectomy
Perioperative outcomes

MP
(n = 24)

SP
(n = 12)

Mean length of stay,
5.9 (2.7)
5.4 (1.4)
days (SD)
Mean EBL, mL (SD)
148 (56)
117 (44.0)
Mean operative time,
418 (68.0) 387 (72.0)
minutes (SD)
Mean lymph node yield, 17.1 (7.5) 11.9 (4.2)
n (SD)
Complication within
10 (41.7)
5 (41.7)
90 days, n (%)
Readmission within
8 (33.3)
3 (25.0)
90 days, n (%)
Positive surgical
1 (4.2)
1 (8.3)
margins, n (%)
EBL = estimated blood loss.

p-Value
0.945
0.080
0.247
0.034
1.000
0.715
0.607
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prostatectomies (RALP) demonstrated a difference in these
perioperative outcomes when comparing cases managed with
the SP and MP platforms.16 This suggests that for surgeons
with prior RARC experience, a majority of their perioperative outcomes are not impacted by a learning curve during the
initial experience with the SP platform.
When combined with prior reports, our experience suggests that the SP platform is a safe, reasonable alternative to
current MP platforms when performing RARC. In a fourpatient case series, Kaouk et al. demonstrated the feasibility
of the SP platform’s use during RARC with no report
of Clavien-Dindo Grade II or greater complication within
30 days.3,4,13 Zhang et al. had similar findings in their fourpatient case series, which involved only one Clavien-Dindo
Grade II 30-day complication.13,17 For MP platform-based
RARC, previous data indicate that Clavien-Dindo Grade II or
greater complication rates at 30 and 90 days can be as high as
50% and 52%, respectively.1,18 Compared to the MP cohort,
the SP platform achieved an overall complication rate of
41.7% at 90 days ( p = 1.000), suggesting patients will not
likely experience increased rates of complications even during the initial learning period of the SP platform.
Our data suggest that lymph node yield is reduced in
RARC where the SP platform is used when compared to the
MP platform. RARCs performed with the SP and MP platforms reported average yields of 11.9 and 17.1 lymph nodes,
respectively ( p = 0.034). Previous literature comparing SP
and MP RALPs also revealed a statistically significant difference in lymph node yield of 12 and 14 lymph nodes, respectively ( p = 0.012).16 Further investigation is warranted
because lymph node yield is a predictor of disease-free and
overall survival.19,20
It is unclear why lymph node yield is lower in RARCs
where the SP platform is used. Both our study and the study
examining SP RALP are comparisons between an initial series of SP procedures and a series of MP procedures by a
surgeon experienced with the MP platform.16 This could
indicate that a learning curve for pelvic lymph node dissection occurs when surgeons experienced with the MP platform transition to the SP platform for RARC. For a surgeon’s
initial experience with MP RARC, lymph node yield was
shown to increase by sequential case number on average by
4.5 lymph nodes for every 10 patients.14,15 Our results and
published studies on SP RALPs failed to show differences
in PSMs and operative times, which are impacted by the
learning curve in the initial experience with MP RARC.16
This suggests that either the reduced lymph node yield is not a
learning curve effect or that a learning curve experienced
during the MP to SP transition uniquely impacts nodal dissection. A larger series of cases is necessary to determine if
this demonstrated difference is reduced through additional SP
RARC experience.
Although we believe this is the largest SP RARC series
available in the literature, this study is limited by its relatively
small sample size and retrospective study design. Specifically, the retrospective design could have introduced bias
through the selection of patients for SP RARC, which was at
the discretion of the operating surgeon. This source of bias in
our study is limited by the propensity matching of subjects
that was used to build the comparison MP cohort. Future
studies should assess these perioperative outcomes as more
SP RARCs are performed.

GROSS ET AL.
Conclusions

The SP platform is a comparable and feasible alternative to
the MP platform when performing RARC based on their
similar perioperative outcomes with the exception of lymph
node yield. Further investigation is necessary to determine if
these outcomes remain similar and if lymph node yield improves as surgeons perform more SP RARCs.
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